Building a pipeline of immuno-therapies to fight against cancer and multiresistant pathogens ALPIONER Therapeutics is a biotech company developing new generation of immunotherapies against cancer and multi-resistant pathogens. Its aT3-plaform is leveraging a bacterial secretion system to inject high quantity of peptides or functional proteins, into the cytosol of the host cell. ALP-102 is a first-in-class vaccine candidate targeting Pa infections while ALP-201-neo is neoantigen-based personnalized cancer vaccine.

70 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

AOBiome is focused on transforming human health by developing microbiome-based therapies for inflammatory conditions. AOBiome Therapeutics, Inc. is a Cambridge, MA-based life sciences company focused on transforming human health by developing microbiome-based therapies for local, nasal and systemic inflammatory conditions. Founded in 2012 by PatientsLikeMe founder Jamie Heywood and MIT-trained Chemical Engineer David Whitlock, AOBiome is advancing a pipeline of multiple, clinical-stage therapeutic candidates. The company's portfolio includes multiple clinical-stage programs: a completed Phase 2 study to treat patients with acne vulgaris or acne, a Phase 1b study to treat patients with pediatric eczema (atopic dermatitis), a Phase 2a study …

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Unlocking the therapeutic potential of protein stabilisation Outrun Therapeutics is unlocking the therapeutic potential of protein stabilisation by E3 Ligase inhibition for the treatment of cancer and other diseases.

163 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Revolutionizing cell therapy for inflammatory diseases via neonatal cardiac progenitor cells and their secretomes Revolutionizing cell therapy to address inflammatory diseases driven via neonatal cardiac progenitor cells and their secretomes.

260 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Entreprise de dispositif médical de diagnostic in vitro : Noratest® In vitro diagnostic medical device Diagnostic, Innovation, Maladies neurodégénératives, Alzheimer, Neurosciences, Entreprise, and Entrepreneuriat

Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Redirecting Immune Memory from Pathogens or Childhood Vaccines to Target Cancer VerImmune is advancing Anti-tumor Immune Redirection (AIR): A Breakthrough Therapy that Redirects Pre-Existing Immune Memory from Childhood Vaccination or Infection to Fight Cancer

188 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

The Precision Vaccines Company Belyntic creates novel vaccines for viral diseases with unmet medical need. We have developed and validated a new platform technology, that generates self-adjuvant synthetic long peptides for a safe and durable induction of cellular immunity. Drug development, Cellular immunity, and Platform technology

165 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Vivet Therapeutics is dedicated to developing innovative gene therapy treatments for orphan diseases. Vivet Therapeutics is focused on optimizing gene therapy through collaborating with the Fundacion para la Investigacion Medica Aplicada (CIMA, Universidad de Navarra) to develop new AAV vectors specifically targeting the liver and generating new technologies to optimize gene delivery and long term expression. Gene Therapy

91 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Shaping the future of in vitro preclinical research Unique R&D platform of donor-derived real human adipose tissue ex vivo for pharmaceutical drug development (obesity, chronic metabolic diseases), dermo-cosmetic, nutraceutical, aesthetic and reconstructive surgery research. ExAdEx-Innov owns exclusive worldwide rights to ExAdEx patented breakthrough technology from French academic laboratories of excellence (Côte d’Azur University, Institut de Biologie Valrose, CNRS, INSERM, University Hospital of Nice) and is supported by SATT Sud-Est, IdEX Université Côte d'Azur, CNRS Innovation, Provence Côte d'Azur Business Incubator, Métropôle Nice Côte d’Azur and Eurobiomed Healthtech Accelerator. adipose tissue, cosmetic testing, research platform, in vitro, ex vivo, models, obesity, …

100 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Transforming cancer and autoimmune treatments with unique IL-1RAP targeting approaches Advesya is a pioneering and transformative biotechnology company developing therapies for difficult-to-treat cancers. Haematology & Oncology, Antibody Drug Conjugate, Cell Therapy, and Autoimmune

398 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Adding Quality Years of Life We are dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

207 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

We build high tech equipment supporting end-to-end development and manufacture of cell and gene therapies. We build high tech equipment supporting end-to-end development and manufacture of cell and gene therapies. biotech, medtech, cell therapy, gene therapy, CAR-T, MSC, iPS, ATMP, Tissue Engineering, cell based therapies, biotherapies, RMAT, and Manufacturing

428 similar entities Tags: FrenchTech2030 Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Expertise in protein engineering | in silico & in vitro antibody discovery platform We work in partnership with technology platforms, pharmaceutical companies, and academic research groups to create next generation cell and molecular therapies. We integrate novel technologies into a synthetic antibody platform to provide the most advanced discovery engine possible.

259 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Science to Transform Lives Immunocore is a leading T cell receptor (TCR) biotechnology company working to create first-in-class biological therapies to address unmet patient needs in oncology as well as infectious and autoimmune diseases. See our community guidelines: http://bit.ly/2kFA8hr Biotechnology, Cancer, Oncology, Infectious Diseases, Autoimmune Diseases, T Cell Receptor, Immunotherapy, ImmTAX, ImmTAC, ImmTAV, and ImmTAAI

264 similar entities Type: Startup Activities: deeptech hrtech biotech Technologies: Synthetic Biology

Inovative company specialized in the development and manufacture of medical devices EOVE develops and manufactures innovatives products to improve care and quality life with greater freedom for Adult ans Pediatric Patients who suffer from breathing disorders and chronic respiratory diseases.

219 similar entities Type: Startup Activities: healthtech manufacturing deeptech Technologies: Synthetic Biology

Platelet-derived Regenerative Therapy for CNS Disorders InVenis Biotherapies is a biotech compagny, spin-off from academic laboratory U1172 and Taipei Medical University, developping innovative regenerative therapies based on blood platelet. Thanks to the high therapeutic potential of our product, we target the most severe diseases involving cell death, as the amyotrophic lateral sclerosis.

217 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

ElyssaMed® will develop the first therapeutic treatment for clinical use comprising several antigenic peptides (epitopes) derived from CTPP and selective for non-small-cell lung cancer, combined with an already marketed vaccine adjuvant. This product once administered to lung cancer patients, will amplify the patients' specific immune responses against tumor cells expressing the antigen CTPP and lead to their destruction.

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

New therapeutic targets based on arsenic trioxide (As2O3) Founded in 2010, MEDSENIC is a biopharmaceutical start-up that aims to exploit the new possibilities offered by the therapeutic use of arsenic trioxide (As2O3) and thereby provide a treatment for patients with autoimmune diseases. santé, biotechnologies, bioparma, biopharmaceutical, biotech, health, biotechnology, autoimmune diseases, and maladies auto-immunes

346 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Design. Formulate. Deliver. ten23 health is the human-centric and sustainable strategic partner of choice for the pharmaceutical industry and biotech start-ups for the development, manufacture, and testing of tomorrow’s medicines. Our sites in Visp and Basel 🇨🇭 support our clients in developing differentiated, stable, usable, and safe injectable treatments for patients. More about us: www.ten23.health biopharmaceuticals, pharmaceutical industry, Contract Manufacturing, Sterile Manufacturing, Aseptic Manufacturing, Drug Device Integration, Analytical Development, Analytical Testing, Molecule Selection, Packaging , and Formulation Development

227 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology

Peptide Chemistry company for design, synthesis, stability studies and chemical optimisation (SAR studies)- CIR agrement PEPTIDES, PEPTIDE LIBRARIES AND PROTEINS Innovative chemistry for therapeutic, diagnostic and cosmetic applications GENEPEP is a CRO company (with CIR agreement) focused on peptide synthesis & services : - Tools for nanoparticles & surface functionalization - Custom synthesis of peptides, proteins & peptide libraries - Catalog of toxins, peptides & pseudopeptides - Design & synthesis for SAR studies (optimisation of solubility, stability, efficacy,...) - Stability & solubility tests - Partner of European programs, ANR, FUI etc...

375 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

OneHealth/AI DeepTech discovering patentable mixes of natural ingredients preserving health and optimizing bioprecesses Alphanosos, a Green One-Health DeepTech company, uses its own Artificial Intelligence algorithms to discover, develop and market active ingredients and products based on blends of extracts from non-pharmaceutical ingredients, in particular edible plants. These active mixtures, some of which are already patented in 15 countries for their antimicrobial activities, are intended for the animal hygiene, dermocosmetics, food preservation and cosmetics sectors, bioprocess optimization and in the longer term, for functional foods and disease treatments. The company began its Research and Development (R&D) activities in mid-2015 and is …

111 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology A.I.

Coave therapeutics Coave Therapeutics is a clinical stage biotechnology company focused on developing life changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases. We are pushing the boundaries of gene therapy through application of our AAV-Ligand Conjugates platform (ALIGATER) that enables targeted delivery, enhanced gene transduction and tissue distribution to improve the effectiveness of advanced gene therapies for rare diseases. Our strategy is to advance a pipeline of novel therapies targeting rare ocular and CNS diseases where targeted gene therapy has the potential to be most effective, where there is a clear unmet need and where success …

86 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology

Automated 3D organoid screening technology We integrate standard assays on chip (eg. CRISPR, T-cell, cytotoxicity) to accelerate drug discovery from target to validation, and advance preclinical predictivity

333 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

A Technology Development and Advisory Company Focused on Medical Devices/Biologics Strategic Advisory Services for both large & small medical device/biologics companies including acquisition, licensing, distribution, joint venture agreements Market, Scientific and Clinical Due Diligence Services Business development Services for venture capital, private equity, hedge funds and investment banking clients & their portfolio companies and clients Product/Device development Strategic Product Postioning including licensing, distribtution and market positioning New Company Formation

520 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Ion channel and GPCR drug discovery using innovative KnotBody technology Maxion uses its innovative KnotBody technology in combination with in vitro display technologies to generate therapeutic candidates against ion channels and GPCR proteins.

186 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Delivering the next generation gene therapies AAVantgarde is a clinical-stage, international biotechnology company (headquartered in Italy) that has developed two proprietary adeno-associated viral (AAV) vector platforms to address the DNA cargo capacity limitations of AAV vectors Gene Therapy, Ophthalmology, and Rare diseases

338 similar entities Type: Startup Activities: healthtech biotech deeptech Technologies: Synthetic Biology

NanoMedSyn develops a new delivery platform to create first-in-class drugs by the engineering with patented AMFA vectors NanoMedSyn was born from the fundamental research of its biologist and chemist founders who discovered a breakthrough technology for drug delivery to the lysosomal cell compartment leading to potentiation of therapeutics. This technology, validated at the preclinical level, has a wide range of applications in the fields of oncology, immunity, inflammation or metabolism. NanoMedSyn’s development plan is based on a strong intellectual property of patented synthetic derivatives called AMFA. The main application is the engineering of recombinant proteins like antibodies or enzymes for …

156 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

AbLeads is a young biotech startup developing innovative solutions in Oncology, through the generation of novel, personalized therapeutic antibodies. Learn More on https://ableads.fr Biotechnology, Oncology, Immunotherapy, Therapeutic Antibodies, and Personalized Medicine

574 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Modulating T-regulatory cells to balance immunity Egle Therapeutics has been founded with a vision to become a game changer in the field of immunomodulating T-regulatory cells (Tregs) through the unique concept of Tregs’ starving while specifically targeting the most immunosuppressive ones.

185 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Building on innovative science to create treatments for patients in need ResoTher Pharma ApS is a biotechnology company focused on developing novel and effective peptide therapeutics for cardiovascular disease by targeting inflammation. Biotechnology, Drug Development, and Pharmaceutical Industry

662 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Affirma Biotech develops new products to overcome the challenge of Multi Drug Resistant and Chronic Infections Affirma Biotech is a start-up company specialized in the discovery and development of new anti-infective drugs via immunomodulation.

438 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Cell Signaling Technology for Organ Repair and Regeneration Cell Signaling Technology for Organ Repair and Regeneration We care for liver Our advanced therapy aims to restore liver function thanks to immunomodulatory and regenerative properties of Hepastem Cell therapy, Acquired liver diseases, Liver diseases, liver based genetic diseases, NASH, ACLF, Antibodies, Clinical stage, Chronic liver disease, Fatty liver, Acute liver disease, Regenerative medicine, Biotech, and Biotechnology

155 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Peptide-based therapeutics for treating peripheral pain conditions At Akasi Pharma, we are developing novel peptide-based therapeutics to treat peripheral pain conditions Peptide therapeutics and Peripheral Neuropathic Pain

141 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

New solutions for autoimmune, inflammatory and bone diseases. BioSenic is an innovative company with the objective of addressing important unmet medical needs in the areas of immunity, auto-immune diseases and organ repair. Cell therapy, Bone and joint tissue regeneration, Osteo-Articular Diseases, autoimmunity, immunity, autoimmune disease, and arsenic

88 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Pioneering therapies based on aptamer technology aptaTargets is a clinical stage biopharmaceutical company focused in developing therapeutic applications based on aptamer technology. Our candidates are neuroprotectants and immunomodulators being developed from preclinical stages up to clinical proof-of-concept. Biopharmaceutical, Biotechnology, Aptamers, Immunology, Stroke, and Inflammatory diseases

133 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering immune interventions to treat chronic disease AstriVax Therapeutics is a European based, clinical-stage biopharmaceutical company, founded in 2022, that is pioneering immune interventions to treat chronic disease. The company has two prototype prophylactic assets in clinical phase and is developing its therapeutic assets to treat chronic HBV and clear high-risk HPV. AstriVax has a novel DNA-launched viral vector immunotherapy platform, Launch-iT, that is designed to create an inherent adjuvant effect to the target antigens, eliciting durable polyfunctional CD8+ and CD4+ T cell responses and robust humoral immunity. Through Launch-iT, the company has the potential to develop best-in-class immunotherapy treatments.

88 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Swedish biotech company exploring reprogramming as the next leap forward in cancer immunotherapy Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies for cancer immunotherapies. Formed as a spin-off from Lund University, the Company is pioneering a gene therapy approach based on its proprietary TrojanDC technology, designed to set in motion immune responses based on the biological properties of professional antigen presenting cells. Backed by Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden, Asgard Therapeutics aims to build a pipeline of personalized cancer immunotherapies optimized to each unique patient. Cell Reprogramming, Cancer Immunotherapy, and …

147 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Novel small-molecule drugs in immunology, fibrosis and women health Clinical-stage biotech company founded by serial entrepreneurs and owned by private & institutional investors. Discovery and development of new chemical entities with strong IP and worldwide rights targeting indications with high unmet medical need in immunology, fibrosis and women health. Medicinal Chemistry, in vitro Pharmacology, Drug Discovery and Development, Inflammation and autoimmune diseases, IP generation, IBD, Ulcerative Colitis, Crohn's disease, Fibrosis, and Uterine fibroids

249 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Aiming to provide improved treatments for chronic respiratory diseases through new, innovative drug substances Aiming to provide improved treatments for chronic respiratory diseases through new, innovative and patent protected substances, thereby reducing suffering and ameliorating quality of life for patients.

380 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Delivering therapies through targeted hyperoxygenation We are developing miniaturized hyperoxygenation therapies! The first application for our technology is miniaturized respiratory assist in patients suffering from lung failure.

60 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology

Revolutionizing drug delivery HHC medical is a health tech startup developing a platform technology for targeted and non-invasive drug delivery via wireless electroporation. Drug Delivery, Genetic therapies, and Enabling life-altering therapies

408 similar entities Type: Startup Activities: deeptech healthtech biotech Technologies: Synthetic Biology

Provider of cells, 3D tissues and testing services. Epithelix Sàrl is a Swiss biotech company specialized in human tissue engineering. Epithelix provides innovative R&D solutions for the study of human respiratory diseases (e.g. Asthma, COPD, Cystic Fibrosis, etc.) and for inhalation toxicity testing of chemicals, while reducing the number of animal experiments. Human pulmonary toxicology, Preclinical Drug Development, and Human Tissue Reconstitution

59 similar entities Type: SMB Activities: biotech deeptech Technologies: 3D Printing Synthetic Biology

Better Technology. Better Delivery. Developing a new generation of disease-modifying therapies. Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic neuromuscular and neurological disorders. Biotechnology, Chemistry, Biology, Bioscience, Life sciences, and Therapeutics

436 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Making Regenerative Medicine Accessible Roumai Medical is developing next-generation biotechnologies in regenerative medicine and human-machine interface to meet the unmet clinical needs of millions of patients worldwide.

398 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

To make disease-modifying treatments available to patients with serious or life-threatening conditions Medibiofarma S.L is a clinical-stage biotechnology company founded in 2016 by a group of professionals with extensive experience in Drug Discovery in the pharmaceutical industry. We aim to generate innovative and high quality research programs based on the modulation of clinically validated therapeutic targets for the treatment of cancer and non-cancer diseases. Medicinal Chemistry, in vitro Pharmacology, Drug Discovery and Development, IP generation, IBD (Colitis, Crohn), Oncology, CNS, and Synaptopathies

540 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

A Swiss Biotech company with a commitment to improving patient outcomes and quality of life in high unmet need diseases Mosanna is a Swiss Biotech company based in Basel with a commitment to improving patient outcomes and quality of life in high unmet need diseases, applying a precision medicine approach. We carefully select innovative medicines for further development using the best contract research organisations in the specific specialised field. Our first goal is to bring an effective and well tolerated medicinal nasal spray to Metabolic Obstructive Sleep Apnea patients.

99 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Precision Drugs against Eucaryotic Pathogens ASTRA Therapeutics is a Drug Discovery company with a mission to design and develop novel, precision engineered drugs against a whole range of Eukaryotic Pathogens.

505 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Ilya Pharma 🇸🇪🇺🇸 is bringing local-acting immunotherapies to patients Ilya Pharma 🇸🇪🇺🇸 is bringing local-acting immunotherapies to patients ATMP, Gene Therapy, Biologics, Drug development, Clinical trials, GMP, Growth, H2020, Uppsala, IBD, Wound treatment, Scar, Topical, Oral, Research, Science, Immunology, Immunophysiology, microbiology, Applied microbiology, Regulatory excellence, Skin, Diabetes, Cutting edge, and IBD

231 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Accelerating drug discovery to transform patients' lives Effective 11/22/21, Acceleron Pharma Inc. is now a wholly-owned subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada) http://merck.com Biopharmaceuticals, Orphan Disease Therapeutics, Rare Diseases, and Serious Diseases

605 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Advancing precision oncology therapeutics designed to deploy multi-faceted inhibition to reverse cancer resistance AUM Biosciences is focused on advancing a clinical pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance biotech, oncology, drug development, Asian-biotech, Precision medicine, Digitalhealth, cancer, and small molecules

550 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Innovation at the service of your health and well-being. Pharmaceutical company, R & AMP; D dedicated to the development and marketing of senolytic compounds, food supplements and aging medications, age -related degenerative diseases and cancer.

322 similar entities Type: SMB Activities: deeptech biotech healthtech Technologies: Synthetic Biology

Transforming Point of Need Multiplex Diagnostics QuantuMDx is a progressive MedTech company passionate about creating multiplex molecular diagnostic solutions for use at the point of need. MedTech, Molecular Diagnostics, Multiplex Molecular Diagnostics, Point of Care, Point of Need, COVID-19, Medical device, Diagnostic device, DNA extraction, TB, Sepsis, Transcriptomics, PCR, Microarray, Assay Development, Assay Feasibility, Rapid Diagnostics, Respiratory Infections, Sexually Transmitted Infections, Host Response, and In vitro Diagnostics

154 similar entities Type: Startup Activities: deeptech biotech healthtech nanotech Technologies: Synthetic Biology

Pioneering inhaled medications for cardiovascular conditions InCarda Therapeutics is a clinical stage drug delivery company pioneering a novel approach of treating cardiovascular diseases and conditions by the inhalation route. The lead product under development is an inhaled therapy to treat a common atrial arrhythmia, paroxysmal atrial fibrillation (PAF). Cardiovascular, Inhalation therapy, Biotechnology, Pharmaceuticals, Clinical Development, Drug Formulation, Commercialization, Clinical Research, Pre-Clinical Research, and Regulatory Affairs

88 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Powering the next wave of genetic medicines through superior delivery ReCode Therapeutics is a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver. RNA Therapies, Genetic Medicines, Non-Viral Lipid Nanoparticles, Genetic Respiratory Disease, Cystic Fibrosis, Primary Ciliary Dyskinesia, and Biotechnology

88 similar entities Type: Startup Activities: deeptech biotech nanotech Technologies: Synthetic Biology

Interventions for Human Diseases Venture-funded company, discovering and developing oral novel small molecule first-in-class inhibitors of Bach1 (a transcription factor) as transformative potential therapy, globally accessible for patients with sickle cell disease (SCD), renal, cardiometabolic and neurodegenerative and other diseases. Sickle Cell Disease, fetal hemoglobin induction, beta-thalassemia, Renal diseases, cardiometabolic diseases, and neurodegenerative diseases

119 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing a new class of ADCs based on NMT inhibition to treat cancer We are a UK biotech company focused on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer.

226 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Developing technologies for the biopharma industry to allow them to treat the root causes of diseases and disorders. Based in Lausanne, Switzerland, NewBiologix SA is a technology innovation company developing a proprietary and breakthrough DNA integration platform for the advanced engineering of human and mammalian cell lines for the improved production of viral vectors used in gene therapies. gene therapy, cell therapy, next-generation sequencing, NGS, rAAV, viral vectors, biologics, stable cell lines, Genomic Integration, stem cell, bioinformatics, capsid optimization, HEK293, gene expression, ATMPs, genomic, epigenetic, transcriptomic, mammalian cell lines, and human cell lines

288 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Creating Tomorrow's Immunotherapies NXI therapeutics focuses on the research and development of a new generation of selective immunosuppressive drugs for autoimmune diseases and transplantations - with objectives of high efficacy, good safety without adverse effects as seen with conventional immunosuppressants.

195 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Transforming the lives of patients through gene therapy uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases. aav, Huntington's disease, gene therapy, ALS, epilepsy, and Fabry disease

160 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Leading the creation of transformative, first-in-class anti-infectives for life-threatening respiratory infections Aridis Pharmaceuticals is a late-stage clinical development company leading the creation of transformative, first-in-class anti-infectives for life-threatening respiratory infections. The company’s pipeline of novel mechanism antibacterial and antivirals, sprung from its proprietary technology platforms, are designed to combat the growing public health threat of antimicrobial resistant bacteria (AMR). Monoclonal Antibody , Infectious Disease, Cell line Engineering, Inhalation therapy

106 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology